hemin
Trade name: Panhematin
Approved
Jul 20, 1983
Hemin (trade name Panhematin) is a protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand, which is is indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women. Manifestations such as pain, hypertension, tachycardia, abnormal mental status and mild to progressive neurologic signs may be controlled in selected patients with this disorder. the therapy for the acute porphyrias is not curative. Heme acts to limit the hepatic and/or marrow synthesis of porphyrin. This action is likely due to the inhibition of δ-aminolevulinic acid synthetase, the enzyme which limits the rate of the porphyrin/heme biosynthetic pathway. The exact mechanism by which hematin produces symptomatic improvement in patients with acute episodes of the hepatic porphyrias has not been elucidated. — NCATS
Clinical trial activity
18 trials · 18 clinical orgs · 1 marketing orgs
Earliest trial started Jul 1, 1993 (NCT00004789)
Timeline
Indications
Approved for
Studied for
- Acute Kidney Injury · Phase 2
- Allografts · Phase 3
- Atherosclerosis · Phase 4
- Coproporphyria, Hereditary · Phase 2
- Diabetes Mellitus · Phase 2
- Gastroparesis · Phase 2
- Healthy Volunteers · Phase 1
- Heme Oxygenase (Decyclizing) · Phase 1
- Kidney Transplantation · Phase 3
- Myelodysplastic Syndromes · Phase 2
- Myocardial Infarction · Phase 1/Phase 2
- Myocardial Ischemia · Phase 2
- Pancreatitis · Phase 2
- Polymorphism, Genetic · Phase 1
- Porphyria, Acute Intermittent · Phase 2
- Porphyrias · Phase 2
- Porphyria, Variegate · Phase 2
- Reperfusion Injury · Phase 3
Mechanism of action
- Delta-aminolevulinic acid dehydrataseANTAGONIST
hemB antagonist
Approval history
- approvedJul 20, 1983
Chemistry & pharmacology
SMILES
[Cl-].[Fe+3].Cc1c(CCC(O)=O)c2cc3[n-]c(cc4nc(cc5[n-]c(cc1n2)c(C=C)c5C)c(C=C)c4C)c(C)c3CCC(O)=O- Mol. weight
- 651.94 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHemin ↗
- NCATS743LRP9S7N ↗
- ChEMBLCHEMBL2096654 ↗
- ChEMBLCHEMBL1200662 ↗
Also known as
- chloro(protoporphyrinato)iron(iii)
- haem arginate
- hämin
- hämin
- hemearginat
- heme arginate
- heme arginate
- heme arginate
- heme arginate complex
- hemin
- hemin
- hemin
- hemin
- hemin
- hemin
- hemin
- hemin
- hémine
- hémine
- hemin for injection
- normosang
- normosang
- panhematin
- panhematin
- panhematin
- panhematin
- protohemin
- protohemin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03646344 | Phase 3 | Sep 30, 2018 | Kidney Research UK, University of Edinburgh |
| NCT02922413 | Phase 2 | Aug 1, 2015 | University of Texas, Galveston |
| NCT02314780 | Phase 2 | Jan 1, 2015 | Medical University of Vienna, University of Vienna |
| NCT02142699 | Phase 2 | Jul 1, 2014 | Medical Research Council, NHS Lothian, University of Edinburgh |
| NCT02180412 | Phase 2 | Apr 1, 2014 | University of Texas, Galveston |
| NCT01855841 | Phase 2 | Apr 1, 2012 | Erasmus University Rotterdam |
| NCT01430156 | Phase 3 | Jan 1, 2012 | NHS Lothian, University of Edinburgh |
| NCT01206582 | Phase 2 | May 1, 2010 | Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Recordati |
| NCT00856817 | Phase 4 | Mar 1, 2009 | Dutch Diabetes Research Foundation, Radboud University |
| NCT00882804 | Phase 1 | Feb 1, 2009 | Mayo Clinic |
| NCT01461512 | Phase 2 | Jan 1, 2009 | University of Vienna |
| NCT00682370 | Phase 1 | Oct 1, 2007 | Medical University of Vienna, University of Vienna |
| NCT00483587 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2007 | University of Groningen |
| NCT00467610 | Phase 2 | May 1, 2007 | Lundbeck, Rush University |
| NCT00004398 | Phase 1 | Jan 1, 1998 | National Center for Research Resources (NCRR), The University of Texas, Dallas |
| NCT00004397 | Phase 1 | Jan 1, 1998 | National Center for Research Resources (NCRR), The University of Texas, Dallas |
| NCT00004396 | Phase 2 | Sep 1, 1997 | National Center for Research Resources (NCRR), The University of Texas, Dallas |
| NCT00004789 | Phase 1/Phase 2 (Phase 2) | Jul 1, 1993 | National Center for Research Resources (NCRR), The University of Texas, Dallas |
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Center for Research Resources (NCRR) | Government | 4 | 4 | 2 | 1993 |
| The University of Texas, Dallas | Academic/Hospital | 4 | 0 | 2 | 1993 |
| University of Edinburgh | Academic/Hospital | 3 | 3 | 2 | 2012 |
| University of Vienna | Academic/Hospital | 3 | 1 | 2 | 2007 |
| Mayo Clinic | Academic/Hospital | 2 | 2 | 2 | 2009 |
| Medical University of Vienna | Academic/Hospital | 2 | 2 | 2 | 2007 |
| NHS Lothian | Academic/Hospital | 2 | 0 | 2 | 2012 |
| University of Texas, Galveston | Academic/Hospital | 2 | 2 | 1 | 2014 |
| Dutch Diabetes Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Kidney Research UK | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Lundbeck | For profit | 1 | 0 | 1 | 2007 |
| Medical Research Council | Government | 1 | 0 | 1 | 2014 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2010 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Recordati | For profit | 1 | 0 | 1 | 2010 |
| Rush University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| University of Groningen | Academic/Hospital | 1 | 1 | 1 | 2007 |